Joseph A Jakubowski
Overview
Explore the profile of Joseph A Jakubowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
2329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortega-Paz L, Franchi F, Rollini F, Galli M, Been L, Ghanem G, et al.
JACC Basic Transl Sci
. 2024 Aug;
9(7):865-876.
PMID: 39170956
This prospective ex vivo and in vitro pharmacodynamic (PD)/pharmacokinetic investigation was conducted in patients with diabetes mellitus with (n = 31) and without chronic kidney disease (n = 30). PD...
2.
Becker K, Kwee L, Neely M, Grass E, Jakubowski J, Fox K, et al.
Sci Rep
. 2020 Apr;
10(1):6169.
PMID: 32277149
Changes in platelet physiology are associated with simultaneous changes in microRNA concentrations, suggesting a role for microRNA in platelet regulation. Here we investigated potential associations between microRNA and platelet reactivity...
3.
Inusa B, Colombatti R, Rees D, Heeney M, Hoppe C, Ogutu B, et al.
J Clin Med
. 2019 Nov;
8(11).
PMID: 31744266
Background: DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) was a Phase 3, randomized, double-blind, placebo-controlled study conducted in children with sickle cell anemia at 51 sites in 13...
4.
Kanter J, Heath L, Knorr J, Agbenyega E, Colombatti R, Dampier C, et al.
Br J Haematol
. 2018 Apr;
184(6):1058-1061.
PMID: 29676449
No abstract available.
5.
Nwankwo J, Gremmel T, Gerrits A, Mithila F, Warburton R, Hill N, et al.
Thromb Res
. 2017 Nov;
160:58-65.
PMID: 29101791
One of the major contributors to sickle cell disease (SCD) pathobiology is the hemolysis of sickle red blood cells (RBCs), which release free hemoglobin and platelet agonists including adenosine 5'-diphosphate...
6.
Heath L, Heeney M, Hoppe C, Adjei S, Agbenyega T, Badr M, et al.
Clin Trials
. 2017 Jul;
14(6):563-571.
PMID: 28743191
Background/aims: Patients with sickle cell anemia can experience recurrent pain episodes, which affect quality of life. The reported prevalence of pain is higher in studies using patient diaries than in...
7.
Moser B, LaBell E, Chigutsa E, Jakubowski J, Small D
Clin Pharmacokinet
. 2017 Jun;
57(2):243-254.
PMID: 28578536
Background And Objective: Prasugrel, a P2Y adenosine diphosphate (ADP) receptor antagonist, inhibits ADP-mediated platelet activation and aggregation in patients with sickle cell anemia (SCA). We developed a population pharmacokinetic (popPK)...
8.
Chan M, Neely M, Roe M, Goodman S, Erlinge D, Cornel J, et al.
Clin Chem
. 2017 May;
63(7):1214-1226.
PMID: 28515099
Background: There are conflicting data on whether changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) concentrations between time points (delta NT-proBNP and hs-CRP) are associated with...
9.
Jakubowski J, Hoppe C, Zhou C, Smith B, Brown P, Heath L, et al.
Thromb Haemost
. 2016 Dec;
117(3):580-588.
PMID: 27929203
Patients with sickle cell anaemia (SCA) have vaso-occlusive crises resulting from occlusive hypoxic-ischaemic injury. Prasugrel inhibits platelet activation and aggregation involved in SCA pathophysiology. Determining Effects of Platelet Inhibition on...
10.
Jakubowski J, Erlinge D, Alexopoulos D, Small D, Winters K, Gurbel P, et al.
Am J Cardiovasc Drugs
. 2016 Nov;
17(2):109-121.
PMID: 27854064
Prasugrel is a third-generation thienopyridine platelet P2Y adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention....